HOXA9 acts as a regulatory switch in acute myeloid leukaemia and myeloproliferative neoplasms
L. Talarmain, M. A. Clarke, D. Shorthouse, J. Fisher, B. A. Hall
The paper investigates HOXA9's role in AML and MPN, showing it acts as a regulatory switch affecting prognosis and clinical outcomes through interactions with JAK2, TET2, RUNX1, and NOTCH.
bioRxiv · Mar 5, 2021Cancer Biology